Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13597306 | 1.00 | CA1 (0.49) | CA1CA2L3MBTL1TDP1MAPT | |
| SCHEMBL11411879 | 0.84 | CA1 (0.62) | CA1CA2L3MBTL1TDP1MAPT | |
| SCHEMBL9242685 | 0.81 | RAB9A (0.65) | CA1CA2L3MBTL1TDP1MAPT | |
| SCHEMBL1556369 | 0.81 | MAPT (0.54) | L3MBTL1MAPTRAB9ATSHRSMN1; SMN2 | |
| SCHEMBL2356142 | 0.79 | SLC6A4 (0.49) | L3MBTL1TSHRLMNAHTR2ASLC6A4 | |
| SCHEMBL1191950 | 0.78 | TDP1 (0.68) | CA1CA2L3MBTL1TDP1MAPT | |
| SCHEMBL8782253 | 0.78 | SLC6A3 (0.61) | CA1CA2L3MBTL1TDP1MAPT | |
| SCHEMBL14047222 | 0.78 | HTR2A (0.66) | L3MBTL1TDP1MAPTSMN1; SMN2LMNA | |
| SCHEMBL15515907 | 0.77 | SLC6A4 (0.47) | L3MBTL1TSHRLMNAHTR2ASLC6A4 | |
| SCHEMBL1339129 | 0.77 | USP2 (0.57) | CA1CA2L3MBTL1TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| EP-2308828-A2 | CaSR antagonist | Japan Tobacco Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| EP-2189439-A2 | CaSR antagonist | Japan Tobacco, Inc. (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-20090326058-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090326058-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090326058-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1619180-B1 | CaSR ANTAGONIST | JAPAN TOBACCO INC (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20080255042-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255042-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-7304174-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7304174-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7304174-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-12-04 | — | — | US | disclosed |
| EP-1619180-A1 | CaSR ANTAGONIST | JAPAN TOBACCO INC. (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | JAPAN TOBACCO INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326058-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | CA1 831/4885CA2 23/4885L3MBTL1 4402/4885 |
| US-20120301552-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | CA1 831/4885CA2 23/4885L3MBTL1 4402/4885 |
| US-20080255042-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | CA1 831/4885CA2 23/4885L3MBTL1 4402/4885 |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | CASR, CALCR, GRK2 | CA1 2231/4885CA2 97/4885L3MBTL1 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.